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Abstract: Ovarian cancer remains the most lethal gynaecological cancer. A better 
understanding of the molecular pathogenesis of ovarian cancer is of critical importance to 
develop early detection tests and identify new therapeutic targets that would increase 
survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to 
meet the energy requirements for increased tumour growth. There is increasing evidence 
that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased 
expression and activity of lipogenic enzymes is largely responsible for increased lipid 
synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article 
reviews the latest knowledge on lipid metabolism and the alterations in the expression of 
lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current 
developments for exploiting lipids as biomarkers for the detection of early stage ovarian 
cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes 
and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. 








Ovarian cancer is the most lethal gynaecological cancer and ranks as the fourth most common cause 
of cancer-related death in women in the Western world [1]. The poor prognosis is largely attributed to a 
lack of early detection and, consequently, approximately 70% of patients present with advanced-stage 
metastatic disease. The treatment for advanced ovarian cancer is debulking surgery followed by 
platinum- and taxane-based chemotherapy. This standard treatment results in a complete response rate 
of 40%–60%; however, more than 90% of patients relapse after 18 months and, with the emergence of 
chemoresistance, ultimately die from the disease [2]. Significant improvements in ovarian cancer survival 
will require the development of more effective molecularly targeted diagnostics and/or therapeutics.  
In recent years, the field of cancer cell metabolism has been progressing rapidly. Cancer cells rely 
on de novo lipid synthesis for the generation of fatty acids to meet the needs of tumour growth, 
resulting in specific alterations in different aspects of lipid metabolism. These alterations can influence 
the availability of structural lipids for the synthesis of membranes, the production and degradation of 
lipids for energy supply and the abundance of lipids with signalling functions. Altered lipid metabolism 
is detected in ovarian cancer patients during early and late stages of disease, including patients with 
recurrent disease, when compared to healthy controls [3,4]. Consequently, there is convincing evidence 
to support a pivotal role of increased lipid synthesis in the development of ovarian cancer. The main 
classes of lipids implicated in the pathogenesis of ovarian cancer include the phospholipids and 
sphingolipids. Multiple pathways are involved in the synthesis and degradation of these lipid groups, 
involving changes in the expression and activity of enzymes regulating their metabolism.  
This article reviews the latest knowledge on lipid metabolism in ovarian cancer cells and the 
alterations in the expression of lipogenic enzymes and signalling pathways. Current developments in 
the application of lipids as biomarkers in the detection of early stage ovarian cancer are discussed. 
Furthermore, research employed to overcome chemotherapy resistance by targeting lipogenic enzymes 
and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. 
2. Lipid Metabolism in Ovarian Cancer 
Abnormal lipid metabolism, leading to increased lipid synthesis, is found to play an important role 
in the pathogenesis of malignancies, including ovarian cancer [5]. Cancer cells depend on de novo lipid 
synthesis for the generation of fatty acids to meet the needs of tumour growth [6]. The increased 
expression and activity of lipogenic enzymes is largely responsible for increased synthesis of  
long-chain fatty acids in cancer cells [7,8]. Changes in the expression and activity of enzymes involved 
in lipid metabolism are regulated by metabolic and oncogenic signalling pathways [9,10]. Common 
enzymes identified in a variety of human malignancies include ATP citrate lyase (ACL), acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (FAS) [7,11,12]. These enzymes are essential in the 
biosynthesis of fatty acids, converting cytosolic citrate to acetyl-CoA (the precursor for fatty acids and 
cholesterol), followed by the production of malonyl-CoA, which is further converted to produce fatty 
acids, respectively. The expression and activity of ACL, ACC and FAS are regulated by complex 
interactions between numerous signalling pathways. For example, the phosphatidylinositol  
3-kinase-Akt (PI3K-Akt) and LKB1/AMPK signalling pathways can increase enzyme activity via 
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direct phosphorylation or by sterol regulatory element-binding protein (SERBP)-mediated transcription 
of lipogenic genes [9,10,13]. Other signalling components, including oncoproteins and tumour 
suppressors, regulate fatty acid synthesis, leading to alterations in the production of fatty acid 
precursors generated from both glucose and glutamine metabolism. In particular, tumour suppressor 
p53 regulates fatty acid synthesis via the pentose phosphate pathway (PPP) and suppresses glucose 
consumption, NADPH production and biosynthesis [14]. The PPP is also regulated by a target protein 
of p53, TIGAR, which decreases levels of fructose-6-phosphate, resulting in an inhibition of glycolysis 
and fatty acid synthesis [15]. p53 can also increase fatty acid synthesis via the enhanced expression of 
glutaminase 2 [16]. The increased synthesis of long-chain fatty acids provides cancer cells with the 
structural building blocks, signalling molecules, post-translational modification of proteins and energy 
required for membrane synthesis, cell survival, proliferation, migration and invasion, which are 
important for the initiation and progression of tumours [17].  
Normal cells acquire fatty acids to meet their metabolic demands from exogenous sources, 
including dietary lipids. A high intake of dietary lipids, including food with a high level of saturated fat 
or cholesterol, such as red meat, eggs and dairy products, is a well a known risk factor for ovarian 
cancer [18–20]. A higher consumption of fats and cholesterol can increase the risk of ovarian cancer 
through increased levels of circulating estrogen and/or progesterone [21]. The exposure of the ovarian 
epithelium to these hormones during ovulation may contribute to malignant transformation and tumour 
development [21,22]. Nonetheless, the increased rate of de novo lipid synthesis that occurs during 
oncogenesis to meet the needs of tumour growth is shown to be irrespective of the nutritional  
load [23]. Interestingly, adipocyte derived lipids were shown to act as an energy source for ovarian 
cancer cells, and co-culture with adipocytes resulted in the transfer of lipids to ovarian cancer cells, 
promoting tumour growth in vitro and in vivo [24].  
Fatty Acid Synthase (FAS) 
The increased expression of fatty acid synthase (FAS) is associated with a poor prognosis in a 
variety of human malignancies, including ovarian cancer [7,25]. The correlation between elevated FAS 
and enhanced tumour growth is attributed to the role of FAS activity in phospholipid synthesis. FAS 
activity is shown to drive phospholipid synthesis in the endoplasmic reticulum (ER), promoting ER 
homeostasis and, consequently, cell survival [26]. Treatment of a variety of cell lines with FAS 
inhibitors induces ER stress in tumour cells, inducing cell death [27] and inhibiting fatty acid  
synthesis [28]. Treatment of SKOV3 human ovarian cancer cells with a synthetic FAS inhibitor (C93) 
led to the activation of AMP-activated protein kinase (AMPK) and cell death [29]. Treatment of 
SKOV3 xenograft bearing mice with C93 also had a significant anti-tumour effect, causing a reduction 
in both tumour growth and volume [29]. The FAS inhibitor C75 has recently been shown to 
significantly reduce cell proliferation and induce apoptosis in ovarian clear cell carcinoma cell  
lines [30] and was attributed to the downregulation of the oncogenic phosphoinositide-3-kinase (PI3K) 
signalling pathway [31]. 
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3. Lipids  
3.1. Phospholipids 
Phospholipids are commonly associated with cancer and have been identified in almost every type 
of malignancy [32]. Phospholipids are a major component of all cell membranes, spontaneously 
forming lipid bilayers. Lysophosphatidic acid (LPA) is a lysophospholipid that functions as an 
extracellular signalling molecule and mediates a variety of biological processes by binding to a family 
of cell surface G protein-coupled receptors [33]. These include LPA receptors belonging to the 
endothelial differentiation gene (Edg) family (LPA1/Edg2, LPA2/Edg4, LPA3/Edg7) [33], the purinergic 
family (GPR23/P2Y9/LPA4) [34] and the related receptors, GPR92/LPA5 [35] and P2Y5/LPA6 [36]. 
Receptors from the purinergic family and related receptors are structurally different to those from the 
well-characterised LPA1–3 receptors [34,37]. LPA receptors, in particular LPA2, are shown to play a 
significant role in the pathogenesis of a variety of human malignancies, including epithelial ovarian 
cancer (EOC) [38,39].  
LPA is secreted by several cell types, detected in many biological fluids, and stimulates cancer cell 
proliferation, migration and survival [40]. High levels of LPA are produced by ovarian cancer  
cells [40–42]. LPA is also elevated in the ascites of ovarian cancer patients [42,43]. It was recently 
demonstrated that LPA in EOC ascites is an important mediator of tumour-promoting effects in 
conjunction with phospholipase A2 (PLA2) activity (discussed below) [44].  
Several studies have demonstrated that LPA activates proteolytic enzymes, including urokinase 
plasminogen activator (uPA) [45–47], matrix metalloproteinases (MMPs) MMP-2 [48] and MMP-9 [49] 
and VEGF [50–52], to augment ovarian cancer invasion and metastasis. The Ras/Rho/ROCK pathways 
are shown to contribute to LPA-induced proteolytic enzyme production [49,53,54]. LPA is shown to 
activate the Ras/Rho/ROCK pathways, to stimulate NF-kB, inducing the expression of MMP-9 and 
uPA, leading to the degradation of the basement membrane and various components of the extracellular 
matrix, respectively [49,55]. Furthermore, the LPA2 receptor was shown to be important in  
LPA-induction of uPA in ovarian cancer cells [46]. Inhibition of LPA2 receptor decreased  
LPA-induced uPA by over 50% and led to a reduction in invasion and migration of ovarian cancer 
cells [46]. Proteolytic enzyme production was also shown to be cell line-specific, where LPA induced 
the expression of uPA in SKOV-3 cells, but not MMP-9, whilst LPA induced the expression of  
MMP-9 in CAOV-3 cells [45,49]. Increased expression of VEGF results in increased angiogenesis 
and, therefore, increased tumour growth [50]. LPA stimulated the transcriptional activity of VEGF 
through c-Myc and Sp-1 independent of HIF-1α [52]. The Rho-ROCK pathway, which lies upstream 
of c-Myc, was also shown to contribute to LPA-induced VEGF expression [52]. 
LPA is also a major regulator of the chemokine growth-regulated oncogene α (GROα). GROα 
expression is identified in a number of human cancers and is associated with tumorigenesis, 
angiogenesis and metastasis [56–58]. More recently, elevated levels of GROα were found in plasma 
and ascites in a high percentage of ovarian cancer patients [59]. In ovarian cancer cell lines, GROα 
expression was not constitutive; however, strongly stimulated by LPA and mediated primarily by 
LPA2 receptors though the transcriptional activation of the GROα promoter [59]. A recent study 
demonstrated that LPA regulates the sterol regulatory element binding protein-FAS (SREBP-FAS) and 
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AMP-activated protein kinase-ACC pathways (AMPK-ACC) resulting in increased de novo lipid 
synthesis in ovarian cancer cells [38]. In addition, LPA-induced lipid synthesis was mediated via  
LPA2 receptors [38], further supporting the importance of LPA2 signalling in the pathogenesis of 
ovarian cancer.  
3.1.1. Autotaxin (ATX) 
Circulating LPA is primarily produced by autotoxin (ATX), a secreted enzyme, which has 
lysophospholipase D activity [60,61]. ATX is a member of the ectonucleotide pyrophosphatase and 
phosphodiesterase family of enzymes. It is a type II membrane protein synthesized as a secreted 
protein. ATX has lysophospholipase D activity, which enables it to convert lysophosphatidylcholine 
(LPC) into LPA [61]. Through its lysophospholipase D activity, ATX has been shown to act as a 
chemotactic factor, to stimulate angiogenesis [62] and to increase invasiveness and metastatic potential 
in transformed cells [63]. ATX was shown to be involved in ascites-induced migration of EOC [44]. 
Interestingly, although increased expression of ATX has been associated with increased cancer 
progression, ATX antigen levels in serum were not increased in ovarian cancer patients when 
compared to healthy controls [64]. Furthermore, ATX may not be useful as a diagnostic marker for 
ovarian cancer, as ATX is also elevated in other conditions, including liver disease, acute coronary 
syndrome and pregnancy [65–67]. 
3.1.2. Phospholipase A  
LPA is also produced by the actions of phospholipase A, PLA1 and PLA2 [68]. High levels of 
cytosolic and calcium-independent PLA2 activity were found in human EOC ascites, concurrent with 
elevated levels of LPC, arachidonic acid, LPA and lipid products of PLA2 [44]. Furthermore, a high 
level of PLA2 activity was observed in EOC tissues when compared to either benign or normal  
tissues [44]. PLA2 in ascites was also shown to induce the proliferation, invasion and migration of 
human EOC [44]. 
3.1.3. Phospholipase D (PLD) 
Phospholipase D (PLD) is an enzyme that converts membrane phospholipids to phosphatidic acid 
(PA), a precursor of LPA. PLD activity is increased in ovarian cancer cells by the integrin receptor 
signalling pathway [69]. PLD is implicated in cell spreading of ovarian cancer cells after PA was 
found to interact directly with Rac1 and to mediate the translocation of GTP-Rac1 to the plasma  
membrane [69]. This activated downstream p21-activated kinase, inducing integrin-mediated 
lamellipodia formation and cell spreading. A number of ovarian cancer cell lines constitutively express 
LPA [70]. In SKOV3 ovarian cancer cells that constitutively produced LPA, inhibition of PLD activity 
resulted in a 50% reduction of LPA levels [70]. Interestingly, OVCAR-3 ovarian cancer cells were 
shown to increase LPA production following treatment with LPA at a concentration similar to that 
found in patient ascites. This was reduced by 60% following the addition of an inhibitor of PLD 
activity [70]. These findings indicate that activity of PLD is associated with both constitutive and 
LPA-induced LPA production in ovarian cancer cells [70]. 




Altered sphingolipid metabolism is also associated with the pathogenesis of a variety of human 
malignancies and includes changes in the levels of sphingolipids and the enzymes involved in their 
metabolism [71]. Ceramides, short chain sphingolipids, have been most extensively studied in cancer, 
due to their involvement in apoptosis. Ceramides are bioactive lipids and are primarily formed by the 
hydrolysis of sphingomyelin, following activation of acid or neutral sphingomyelinase or by de novo 
synthesis involving N-acylation of dihydrosphingosine [72]. They are proapoptotic metabolites and 
known tumour-suppressors. The administration of ceramide analogues can inhibit tumour growth in a 
variety of cancer cell lines, both in vitro and in vivo [73–76]. Regulated by many enzymes, ceramides 
give rise to more complex sphingolipids, including sphingosine 1-phosphate (S1P), a bioactive lipid 
shown to promote cell survival. S1P is formed following activation of the enzyme sphingosine kinase 
(SphK). The isoform SphK1 is activated in human ovarian cancer cells, leading to resistance to the 
chemotherapy drug, 4-HRP [77]. The ability of S1P to facilitate the survival of cancer cells is in direct 
contrast to the proapoptotic activity of ceramide, and consequently, it is suggested that the ratio of 
these two lipids are important in cancer development [78,79].  
3.3. Glycosphingolipids  
Ceramides can also lead to the synthesis of glycosphingolipids, including sulphatides and 
gangliosides. Sulphatides (ST), membrane-sulphated glycolipids, have been reported to be elevated in 
ovarian cancer [80,81]. Microarray analysis revealed an increase in the mRNA expression of enzymes 
involved in ST synthesis in microdissected epithelial ovarian cancer cells, when compared to normal 
tissue [80]. However, their role in the pathogenesis of ovarian cancer remains to be elucidated.  
4. Lipids as Diagnostic Markers and Therapeutic Targets in Ovarian Cancer  
4.1. Diagnostic Markers 
Lipid biomarker discovery is of particular interest in ovarian cancer, as mortality could be reduced 
significantly by an early detection test. However, only a few studies have been reported to date 
investigating lipids as diagnostic ovarian cancer markers. Some promising lipid biomarkers are shown 
in Table 1. Studies investigating the potential role for LPA as an early detection marker presented 
conflicting results. LPA levels were shown to be significantly elevated in ovarian cancer patients when 
compared to controls in some studies [4,41]; however, other researchers found no differences [43] or 
even contrary results [4]. These differing results can potentially be attributed to differing methodology 
and/or sample type. An ongoing clinical trial is currently validating the utility of a new assay for LPA 
for the early detection of ovarian cancer [82]. 
Analysis of EOC tissue using liquid chromatography electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS) revealed elevated levels of sulphatides (ST) when compared to normal 
ovarian tissue [80]. Matrix-assisted laser desorption ionization-tissue-imaging MS detected, as well as 
localized, ST in areas of epithelial ovarian carcinoma, further supporting the potential of ST as a 
biomarker in ovarian cancer. Using fluorometric assays, PLA2 was identified as a potential diagnostic 
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maker after increased activity levels were observed in human EOC tissues when compared to either 
benign or normal tissues [44].  
Table 1. Altered lipid metabolism in ovarian cancer: potential diagnostic markers.  
Marker Studies/Methods References 
LPA LPA assays under development in clinical trials. [82] 
Sulphatides 
Elevation of sulphatides in EOC tissue compared to normal tissue by mass 
spectrometry (LC ESI-MS/MS). 
[80] 
PLA2 
Elevated activity of PLA2 in EOC tissue, compared to benign tumours and 
normal tissue using fluorometric assays. 
[44] 
LPLs 
Increased levels of LPA, LPI and SIP in plasma from ovarian cancer 
patients compared to healthy controls using ESI-MS.  
Predictive markers with a significant difference between levels of SIP, LPA 





LPLs + CA 125 
Serum measurements of LPLs in conjunction with CA125 greatly improved 
diagnostic accuracy in early stage serous ovarian cancer and mucinous 
subtypes using LC ESI-MS/MS. 
[83] 
Abbreviations: PLA2, phospholipase A2; LPLs, lysophospholipids; LPA, lysophosphatidic acid; LPI, 
lysophosphatidylinositol; LPC, Lysophosphatidylcholine; SIP, sphingosine-1-phosphate; LC ESI-MS/MS, liquid 
chromatography electrospray ionization-tandem mass spectrometry; ESI-MS, electrospray ionization mass spectrometry. 
Lysophospholipids (LPLs) might also have potential as diagnostic and/or predictive ovarian cancer 
markers [3,41,83]. Elevated levels of LPA and lysophosphatidylinositol (LPI) were found in plasma of 
ovarian cancer patients using electrospray ionization-tandem mass spectrometry (ESI-MS) [3]. ESI-MS 
also identified a significant difference in plasma levels of LPA, LPI and sphingosine-1-phosphate 
(SIP) when comparing patient and control samples [41]. The potential value of LPLs as predictive 
markers arose after significant differences between levels of SIP, LPA and lysophosphatidylcholine 
(LPC) were identified between preoperative and postoperative serum samples [41]. The measurement 
of bioactive phospholipids, LPA, LPI, LPC and SIP, in conjunction with serum CA125 using LC  
ESI-MS/MS improved the accuracy of diagnosing early stage serous ovarian cancers from 65% to 82% 
and mucinous cancers from 44% to 88% [83]. 
4.2. Therapeutic Targets 
Lipogenic enzymes and lipids are increasingly seen as potential targets of novel anti-ovarian cancer 
therapies. Potential components of aberrant metabolic lipid pathways, which might serve as targets to 
inhibit cancer growth and/or to overcome chemotherapy resistance, are listed in Table 2. 
Statins are inhibitors of cholesterol synthesis, but also of the production of molecules, such as 
isoprenoids. These are lipid anchors for a range of signalling proteins, such as the small GTPases, Ras 
and Rho [84]. The statin lovastatin has recently been reported to induce apoptosis of ovarian cancer 
cells in a p53-independent manner and to synergize with doxorubicin, a chemotherapeutic agent used 
to treat recurrent ovarian cancer. Lovastatin drives ovarian tumour cell death by two mechanisms: first, 
by blocking HMG-CoA reductase activity, and second, by sensitizing multi-drug resistant cells to 
doxorubicin by a novel mevalonate-independent mechanism [85]. The efficacy of statins in  
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anti-ovarian cancer therapy is currently examined in a phase II clinical study of interaction of 
lovastatin and paclitaxel for patients with refractory or relapsed ovarian cancer [86].  
To overcome chemotherapy resistance, the effects of co-administration of ceramide with 
chemotherapy agents has been investigated. In human ovarian cancer cells, the co-administration of 
ceramide with the chemotherapy drug paclitaxel sensitized the cancer cells and doubled cell death 
when compared to treatment of ovarian cancer cells with paclitaxel alone [87]. In addition, following 
paclitaxel treatment, the expression of ceramide transport protein (CERT) was increased in 
chemotherapy resistant cell lines and in tumour samples of ovarian cancer patients [88]. CERT 
transports ceramide generated by de novo synthesis from the ER to the Golgi apparatus, where it is 
converted to sphingomyelin [89]. Knockdown of CERT resulted in an accumulation of ceramide in the 
ER, increasing ER stress and sensitivity of cancer cells to paclitaxel treatment [88]. Consequently, 
ceramide has also become a therapeutic target in ovarian cancer.  
Table 2. Altered lipid metabolism in ovarian cancer: potential therapeutic targets. 
Target Treatment Effect References 
Cholesterol Statins Induce apoptosis of ovarian cancer cells. In clinical trials. [85,86] 
FAS 
C93 
Increases cytotoxicity of carboplatin and paclitaxel. Induces cell death  
in vitro and reduces tumour growth in xenograft mouse model. 
[25,29] 
C75 
Reduces cell proliferation in ovarian clear cell carcinoma cell lines. Inhibits 
growth and survival of ovarian cancer cells in vitro.  
[30,31] 
ATX ccPA Increases cytotoxicity of carboplatin. [90] 
ENPP2 siRNA Increases apoptosis of cancer cells with carboplatin. [90] 
Ceramide Ceramide 
Co-administration with the chemotherapy drugs, paclitaxel or carboplatin, 
sensitises cancer cells, increasing cell death. 
[87] 
CERT siRNA Sensitises cancer cells to paclitaxel. [88] 
Abbreviations: Fas, fatty acid synthase; ATX, autotaxin; ccPA, 2-carbacyclic phosphatidic acid; ENPP2, ectonucleotide 
pyrophosphatase/phosphodiesterase 2; CERT, ceramide transport protein. 
The FAS inhibitor, C93, has been shown to greatly increase the cytotoxicity of the chemotherapy 
drugs carboplatin and paclitaxel in ovarian cancer cells [25], thereby highlighting the potential of this 
inhibitor as a drug to overcome chemotherapy resistance and disease recurrence. A more recently 
identified inhibitor of FAS, P75, significantly reduced cell proliferation in ovarian clear cell  
carcinoma [30] and decreased cell proliferation and induced apoptosis in ovarian cancer cells [31]. 
The gene ectonucleotide, pyrophosphatase/phosphodiesterase 2 (ENPP2), which encodes ATX, was 
identified as a potential gene causing platinum-resistance in ovarian cancer [90]. Inhibition of ENPP2 
and ATX using siRNA and 2-carbacyclic phosphatidic acid, respectively, led to increased  
carboplatin-induced apoptosis of ovarian cancer cells. In addition, expression of ATX in the ovarian 
cancer cell line, OVCAR-3, delayed apoptosis, suggesting that ATX inhibits cell death induced by the 
chemotherapy drug carboplatin [90]. 
  




Abnormal lipid metabolism plays an important role in the pathogenesis of ovarian cancer. The 
activity of lipid metabolizing enzymes is regulated by a complex interplay between metabolic and 
oncogenic signalling pathways. Components of the aberrant lipid metabolism pathways are promising 
targets for the development of novel ovarian cancer diagnostics and therapeutics. Several diagnostic 
markers with potential for the early detection of ovarian cancer have been identified. LPA and LPLs 
show the most promise, with elevated plasma levels identified in ovarian cancer patients. Therapeutic 
targets that have shown the greatest potential include statins, as well as ceramides. Both statins and 
ceramides are successful in inducing ovarian cancer cell death, as well as sensitising cancer cells to 
chemotherapeutic drugs. FAS inhibitors, C93 and C75, which inhibit the growth and survival of 
ovarian cancer cells, also show promise. LPA and statins are currently under investigation in clinical 
trials for their potential in the detection and treatment of ovarian cancer, respectively. This review 
highlights the important role of abnormal lipid metabolism in the development and progression of 
ovarian cancer. 
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